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Genome-wide association studies (GWAS) and large-scale 
replication studies have identified common variants in  
79 loci associated with breast cancer, explaining ~14% of 
the familial risk of the disease. To identify new susceptibility 
loci, we performed a meta-analysis of 11 GWAS, comprising 
15,748 breast cancer cases and 18,084 controls together with 
46,785 cases and 42,892 controls from 41 studies genotyped 
on a 211,155-marker custom array (iCOGS). Analyses were 
restricted to women of European ancestry. We generated 
genotypes for more than 11 million SNPs by imputation using 
the 1000 Genomes Project reference panel, and we identified 
15 new loci associated with breast cancer at P < 5 × 10−8. 
Combining association analysis with ChIP-seq chromatin 
binding data in mammary cell lines and ChIA-PET chromatin 
interaction data from ENCODE, we identified likely target 
genes in two regions: SETBP1 at 18q12.3 and RNF115 and 
PDZK1 at 1q21.1. One association appears to be driven by an 
amino acid substitution encoded in EXO1.
Breast cancer is the most common cancer in women worldwide1. 
The disease aggregates in families and has an important inherited 
component. This inherited component is driven by a combination of 
rare variants, notably in BRCA1, BRCA2, PALB2, ATM and CHEK2, 
conferring a moderate or high lifetime risk of the disease, together 
with common variants at more than 70 loci identified through 
GWAS and large-scale replication studies2–20. Taken together, these 
loci explain approximately one-third of the excess familial risk of 
breast cancer.
The majority of susceptibility SNPs have been identified through 
the Breast Cancer Association Consortium (BCAC), a collaboration 
involving more than 50 case-control studies. We recently reported the 
results of a large-scale genotyping experiment within BCAC, which 
used a custom array (iCOGS) designed to study variants of interest 
for breast, ovarian and prostate cancers. iCOGS comprised more than 
200,000 variants, of which 29,807 had been selected from combined 
analysis of 9 breast cancer GWAS involving 10,052 breast cancer cases 
and 12,575 controls of European ancestry. In total, 45,290 breast 
cancer cases and 41,880 controls of European ancestry from 41 studies 
were genotyped with iCOGS, leading to the discovery of 41 new 
susceptibility loci16. A parallel analysis identified four loci specific 
to estrogen receptor (ER)-negative disease17. However, additional 
susceptibility loci may have been missed because they were not 
selected from the original GWAS or were not included on the array.
Genotype imputation is a powerful approach to infer missing geno-
types using the genetic correlations defined in a densely genotyped 
reference panel, thus providing the opportunity to identify new sus-
ceptibility variants even if they are not directly genotyped21. In this 
analysis, we aimed to identify additional breast cancer susceptibility 
loci by using data from all ~200,000 variants on the iCOGS array, and 
we used imputation to estimate genotypes for more than 11 million 
SNPs. We applied the same approach to data from 11 GWAS. After 
quality control exclusions, the data set comprised 15,748 breast can-
cer cases and 18,084 controls from GWAS together with 46,785 cases 
and 42,892 controls from 41 studies genotyped with iCOGS (Online 
Methods and Supplementary Table 1). All subjects were women of 
European ancestry.
We imputed genotypes using the 1000 Genomes Project March 
2012 release as the reference data set (Online Methods). The main 
analyses were based on ~11.6 million SNPs that were imputed with 
imputation r2 >0.3 and had minor allele frequency (MAF) >0.005 in 
at least one of the data sets22.
Of common SNPs (MAF > 0.05), 88% were imputed from the 
iCOGS array with r2 >0.5, compared with 99% of variants for the 
largest GWAS (UK2), which was genotyped using arrays with 594,375 
SNPs (Fig. 1a,b and Supplementary Table 2)9. Of common SNPs, 
37% were imputed on the iCOGS platform with r2 >0.9, in compari-
son to 85% for UK2. Thus, despite the iCOGS array being designed 
as a follow-up of GWAS for different diseases rather than a genome-
wide array, the majority of common variants could be imputed using 
this array, but the overall imputation quality was poorer than from a 
standard GWAS array. Imputation quality decreased with decreasing 
allele frequency (Fig. 1c,d and Supplementary Table 2).
We calculated log odds ratio (OR) estimates and standard errors 
for each data set using logistic regression, adjusting for principal 
components when this adjustment was found to substantially reduce 
the inflation factor. We then combined the results from each data set 
for variants with MAF >0.5% using a fixed-effects meta-analysis23. 
We identified more than 7,000 variants with combined P < 5 × 10−8  
for association, the large majority of which were in regions previ-
ously shown to be associated with breast cancer susceptibility. 
Of the 79 previously published breast cancer susceptibility loci 
identified in women of European ancestry, all but 8 showed evidence 
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of association at P < 5 × 10−8 for overall, 
ER-positive or ER-negative disease risk 
(Supplementary Table 3). For four of the 
eight variants (rs1550623 at 2q31, rs11571833 
at 13q13.1, rs12422552 at 12p13.1 and 
rs11242674 at 6p25.3), we observed slightly 
weaker evidence of association. One reported 
variant, rs7726159, did not show association 
reaching P < 5 × 10−8 in this (P = 0.0017) 
or the previous analysis; it was identified 
through fine mapping of the TERT region 
at 5p15.33 (ref. 18). One other variant in 
AKAP9, rs6964587, reported previously19, 
did not show association reaching P < 5 × 
10−8, but another variant correlated with it 
did (P = 3.67 × 10−8 for chr7:91681597:D; r2 
between the two markers = 0.98). The two 
remaining variants (rs2380205 at 10p15 and 
rs1045485 at CASP8) were reported in earlier analysis9,24 but did not 
have associations even reaching P < 0.0001, suggesting that these 
loci might have been false positive reports. An alternative variant 
at CASP8, rs1830298 (r2 = 0.06, D′ = 1 with rs1045485 in the 1000 
Genomes Project CEU population (Utah residents of Northern and 
Western European ancestry)), did show association reaching P < 5 × 
10−8 in this data set25.
To assess evidence for additional susceptibility loci, we removed all 
SNPs within 500 kb of susceptibility variants identified previously in 
women of European ancestry2–14,16–19, leaving 314 variants from 27 
regions associated with breast cancer at P < 5 × 10−8 (Supplementary 
Figs. 1 and 2). We observed the strongest associations in a 610-kb 
interval (Build 37 coordinates 28,314,612–28,928,858) on chromo-
some 22 (smallest P = 8.2 × 10−22, for rs62237573). This interval lies 
approximately 100 kb centromeric to CHEK2, and further analysis 
showed that the associated SNPs were correlated with the CHEK2 
founder variant c.1100delC (strongest correlation r2 = 0.39 for SNP 
rs62235635). CHEK2 c.1100delC is known to be associated with breast 
cancer from candidate gene analysis but has not previously gener-
ated an association in GWAS26,27. We performed an analysis adjust-
ing for CHEK2 c.1100delC using data on ~40,000 samples that had 
been genotyped for this variant. The strongest associated variant in 
this subset was rs140914118; after adjustment for c.1100delC, the 
statistical significance of the rs140914118 association was markedly 
diminished (P = 3.1 × 10−9 to P = 0.78; Supplementary Fig. 3a,b), 
suggesting that this signal is driven by CHEK2 c.1100delC.
Variants in four regions (DNAJC1, 5p12, PTHLH and MKL1) lay 
within 2 Mb of a previously published breast cancer–associated SNP. 
In each case, these associations became weaker (no longer having 
P < 5 × 10−8) after adjustment for the previously associated SNP(s) 
in the region (data not shown). For four other regions, the signifi-
cantly associated variants were identified in just one GWAS and failed 
imputation (r2 < 0.3) in the remaining data sets, including iCOGS; 
we did not consider these variants further.
To confirm the results for the remaining 18 regions, we per-
formed reimputation in the iCOGS data set without prephasing 
(Online Methods). Fifteen loci remained associated with breast can-
cer at P < 5 × 10−8 (Table 1 and Supplementary Table 4). For three 
of the loci, the most significant SNP, or a highly correlated SNP, had 
been directly genotyped on iCOGS (Supplementary Table 5); one, 
rs11205277, had been included on the array because it is associated 
with adult height28, whereas the other two were selected on the basis 
of evidence from the combined breast cancer GWAS but failed to 
reach genome-wide significance in the earlier analyses. We attempted 
to genotype the 12 remaining variants on a subset of ~4,000 sam-
ples to confirm the quality of the imputation (10 variants could be 
directly genotyped; for one region, an alternative, correlated variant 
was selected) (Supplementary Table 5). For the 11 variants that could 
be assessed, the r2 estimates of correlation between the observed and 
imputed genotypes were close to the r2 values estimated in imputa-
tion. Furthermore, the estimated effect sizes in the subset of individu-
als we genotyped were similar to those obtained from the imputed 
genotypes (Supplementary Table 5). These results indicate that the 
analyses based on imputed genotype data were reliable.
There was little or no evidence of heterogeneity in the per-allele OR 
estimates among the studies genotyped using iCOGS (Supplementary 
Fig. 4 and Supplementary Table 6). There was little evidence for 
departure from a log-additive model for any locus, except for a 
borderline departure for rs6796502 (P = 0.049) for which the OR 
estimates for heterozygotes and homozygotes for the risk-associated 
allele were similar (Supplementary Table 6).
The estimated OR values for invasive versus in situ disease were 
similar for all the loci (P > 0.05) (Supplementary Table 7). For four 
of the loci (rs12405132, rs12048493, rs4593472 and rs6507583), the 
association was stronger for ER-positive disease (case-only P < 0.05) 
(Supplementary Table 8). Seven of the loci were associated with 
ER-negative disease (P < 0.05), but none had a stronger association 
for ER-negative than ER-positive disease. Two of the loci showed 
Figure 1 Histograms of imputation r2.  
(a) Histogram of imputation r2 for the  
iCOGS array for variants with MAF >0.05.  
(b) Histogram of imputation r2 for the  
UK2 GWAS for variants with MAF >0.05.  
(c) Histogram of imputation r2 for the iCOGS 
array for variants with MAF ≤0.05.  
(d) Histogram of imputation r2 for the UK2 
GWAS for variants with MAF ≤0.05. F
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significant trends in OR by age at diagnosis: for rs13162653, the OR 
was higher at younger ages (P = 0.007), whereas for rs6507583 the OR 
was higher at older ages (P = 0.006) (Supplementary Table 9). One 
of the variants (chr17:29230520:D in ATAD5) was correlated with a 
variant that has also been shown to be associated with serous ovarian 
cancer in a meta-analysis29 (r2 = 0.93 between chr17:29230520:D and 
chr17:29181220:I).
To approach the task of identifying the likely causal variants and 
genes underlying these associations, we first defined the set of all 
SNPs that were correlated with each of the 15 lead SNPs and that could 
not be ruled out as potentially causal (on the basis of a likelihood 
ratio of 100:1)30, resulting in a subset of 522 variants (Supplementary 
Table 10). One of the variants, rs72755295, lies in an intron of EXO1, 
which encodes a protein involved in mismatch repair. This variant was 
strongly correlated with only one other variant, rs4149909, coding for 
an amino acid substitution in EXO1 (p.Asn279Ser; with a Combined 
Annotation-Dependent Depletion (CADD) score of 33, indicating 
that it is likely to be deleterious)31, suggesting that this variant is likely 
to be functionally related to breast cancer risk. None of the remain-
ing SNPs lay within gene-coding sequences, consistent with previous 
observations that most common cancer susceptibility variants are 
regulatory. For each of the remaining 520 variants, we then looked for 
enhancer elements in mammary cell lines, on the basis of Encyclopedia 
of DNA Elements (ENCODE) chromatin immunoprecipitation and 
sequencing (ChIP-seq) data32,33. To identify potential gene targets, 
we combined this information with ENCODE chromatin interaction 
analysis with paired-end tag (ChIA-PET) chromatin interaction data. 
We identified two regions in which the associated variants overlapped 
with putative enhancer sequences and for which consistent promoter 
interactions were predicted (Table 1). For rs12405132 at 1q21.1, we 
identified four potential interacting genes: RNF115, POLR3C, PDZK1 
and PIAS3 (Fig. 2). Of these, the strongest evidence was for RNF115 
and PDZK1; 3 of the 64 potentially causal variants lay in interacting 
enhancer regions. RNF115 (also known as BCA2) encodes an E3 ubiq-
uitin ligase RING finger protein that is overexpressed in ER-positive 
breast cancers34. PDZK1 encodes a scaffold protein that connects 
plasma membrane proteins and regulatory components, regulating 
their surface expression in epithelial cell apical domains, and has been 
proposed to act as an oncogene in breast cancer35.
SNPs correlated with rs6507583 at 18q12.3 lay in regions inter-
acting with the promoter of SETBP1 (Supplementary Fig. 5). The 
encoded SETBP1 protein has been shown to bind the SET nuclear 
oncoprotein, which is involved in DNA replication.
We used data from The Cancer Genome Atlas (TCGA) to assess 
associations between the 15 newly discovered susceptibility variants 
and expression of neighboring genes in breast tumors and normal 
breast tissue. One SNP, rs7707921, was strongly associated with RPS23 
expression in all tissues (Supplementary Fig. 6 and Supplementary 
Table 11). However, we observed stronger associations with expres-
sion for more telomeric SNPs that were less strongly associated with 
disease risk (top expression quantitative trait locus (eQTL) SNP 
rs3739: P = 1 × 10−23, P value for disease risk = 5.28 × 10−7), sug-
gesting that this association might be coincidental. SNP rs7707921 
was also more weakly associated with the expression of ATP6AP1L  
(P = 5.6 × 10−5 in tumors, P = 0.066 in normal tissue).
On the basis of the estimated OR values in the iCOGS stage (all 
but one of which were in the range 1.05–1.10) and assuming that all 
loci combine multiplicatively, the 15 new loci identified here would 
explain a further ~2% of the twofold risk of breast cancer in the 
first-degree relatives of women with the disease. Taking the newly 
identified loci together with previously identified ones, more than 90 
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independent common susceptibility loci for 
breast cancer have been identified, explain-
ing ~16% of the familial risk. We estimate, 
assuming a log-additive model, that on the 
basis of genotypes for variants at these loci 
approximately 5% of women in the general 
population have >2-fold increased risk of 
breast cancer and 0.7% of women have >3-fold 
increased risk. In the current analyses, more 
than 50% of variants with MAF >0.005 in 
subjects of European ancestry could be imputed well (r2 > 0.5). These 
results suggest that, although there may be further susceptibility vari-
ants with comparably associated effects that were not well imputed, 
the identification of many additional loci will require larger associa-
tion studies. In the meantime, inclusion of these additional loci in 
polygenic risk scores will improve the ability to discriminate between 
individuals at high and low risk, potentially improving breast cancer 
screening and prevention.
URLs. Breast Cancer Association Consortium (BCAC), http://apps.
ccge.medschl.cam.ac.uk/consortia/bcac/index.html; Collaborative 
Oncological Gene-environment Study (COGS), http://www.cogseu.
org/; ENCODE, http://www.genome.gov/encode/ and http://
genome.ucsc.edu/ENCODE/; iCOGS, http://www.nature.com/icogs/  
and http://ccge.medschl.cam.ac.uk/research/consortia/icogs/; 
IMPUTE, http://mathgen.stats.ox.ac.uk/impute/impute.html; MACH, 
http://csg.sph.umich.edu/abecasis/MACH/download/; SHAPEIT, 
https://mathgen.stats.ox.ac.uk/genetics_software/shapeit/shapeit.
html; TCGA, http://cancergenome.nih.gov/; 1000 Genomes Project, 
http://www.1000genomes.org/.
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version of the paper.
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Study overview. Details of the subjects, genotyping and quality control 
measures for the GWAS and iCOGS data are described elsewhere12,14,16,36,37. 
All participating studies were approved by their appropriate ethics review 
boards, and all subjects provided informed consent. Analyses were restricted 
to women of European ancestry. All imputations were performed using the 
1000 Genomes Project March 2012 release as the reference panel. Of the 11 
GWAS, 8 (C-BCAC) plus a subset of the BPC3 GWAS (CGEMS) were used 
in the combined GWAS analysis that nominated 29,807 SNPs for the array. 
The BPC3 and TNBCC GWAS nominated additional SNPs with evidence for 
association with ER-negative or triple-negative (ER-, progesterone receptor 
(PR)- and HER2- negative) breast cancer. The EBCG GWAS was not used 
to nominate SNPs for the iCOGS array. For eight GWAS (C-BCAC), geno-
types were imputed in a 2-stage procedure, using SHAPEIT to derive phased 
genotypes and IMPUTEv2 to perform imputation on the phased data22. We 
performed imputation using 5-Mb non-overlapping intervals for the whole 
genome. OR estimates and standard errors were obtained using logistic 
regression with SNPTEST21. For two of the studies, we adjusted for the three 
leading principal components, as this adjustment was found to materially 
reduce the inflation factor; for the rest of the studies, no such adjustment was 
necessary. For the remaining three GWAS (BPC3, TNBCC and EBCG), impu-
tation was performed using MACH and Minimac23. Genomic control adjust-
ment was applied to each GWAS as previously described16. The iCOGS data 
were also imputed in a two-stage procedure using SHAPEIT and IMPUTEv2, 
again using 5-Mb non-overlapping intervals. We split the ~90,000 samples into 
10 subsets, keeping subjects from the same study in the same subset where 
possible. We obtained OR estimates and standard errors using logistic regres-
sion adjusting for study and nine principal components. For regions showing 
evidence of association, we repeated imputation in iCOGS, using IMPUTEv2 
but without prephasing in SHAPEIT to improve imputation accuracy. We also 
increased the number of Markov chain Monte Carlo (MCMC) iterations from 
30 to 90 and increased the buffer region from 250 kb to 500 kb.
Meta-analysis. OR estimates and standard errors were combined in a 
fixed-effects inverse variance meta-analysis using METAL23. For the GWAS, 
results were included in the analysis for all SNPs with MAF >0.01 and 
imputation r2 >0.3, except for the triple-negative GWAS, where the criteria 
were r2 >0.9 and MAF >0.05. For iCOGS, we included all SNPs with r2 ≥0.3 
and MAF >0.005.
Confirmatory genotyping. The best variant in each region after reimpu-
tation and meta-analysis was genotyped in 4,123 samples from SEARCH, 
using TaqMan assays according to the manufacturer’s instructions. Squared 
correlations between the observed genotypes and the genotypes estimated 
by imputation are shown in Supplementary Table 5. For all imputed SNPs, 
the squared correlations were >0.7, the call rates were ≥0.98 and there was no 
evidence of departure of genotype frequencies from those expected under 
Hardy-Weinberg equilibrium (P > 0.1).
eQTL analyses. Germline genotype, mRNA expression and somatic copy 
number data for samples taken from breast tumors and tumor-adjacent nor-
mal tissue were obtained from the TCGA38. Copy number and genotype data 
were obtained using the Affymetrix Genome-Wide Human SNP 6.0 platform. 
For mRNA expression data, we used the expression profiles obtained with the 
Agilent G4502A-07-3 microarray. Genotype data were subjected to the follow-
ing quality control filters. SNPs were excluded in case of low frequency (MAF 
<1%), low call rate (<95%) or departure from Hardy-Weinberg equilibrium at 
P < 1 × 10−13. Individuals were excluded on the basis of low call rate (<95%) or 
high heterozygosity (false discovery rate (FDR) < 1%). Furthermore, individu-
als were also excluded in case of non-European ancestry or male sex. Quality 
control and intersection with the other genomic data types resulted in 380 
tumor samples and 56 normal samples.
Genotype data were imputed as described above. eQTL analysis was 
performed using linear regression with SNPTEST, regressing the mRNA 
expression levels of selected candidate genes on the imputed genotype. For 
each gene, we performed eQTL analysis against every microarray probe that 
uniquely mapped to that gene. We adjusted the analyses for the somatic copy 
number of the gene and for SNPs that intersected the probe sequence, provided 
that the MAF for these SNPs exceeded 1% in individuals of European ancestry 
in the 1000 Genomes Project data.
Enhancer analyses. Maps of enhancer regions with predicted target 
genes were obtained from Hnisz et al.33 and Corradin et al.32. Enhancers 
active in the mammary cell types MCF-7, HMEC and HCC1954 were 
intersected with candidate causal variants using Galaxy. ENCODE ChIA-PET 
chromatin interaction data from MCF-7 cells (mediated by RNA polymerase 2 
and ERα) were downloaded using the UCSC Table browser. Galaxy was 
used to identify the ChIA-PET interactions between an implicated mam-
mary cell enhancer (containing a strongly associated variant) and a predicted 
gene promoter (defined as regions 3 kb upstream and 1 kb downstream of 
the transcription start site).
36. Ahsan, H. et al. A genome-wide association study of early-onset breast cancer 
identifies PFKM as a novel breast cancer gene and supports a common genetic 
spectrum for breast cancer at any age. Cancer Epidemiol. Biomarkers Prev. 23, 
658–669 (2014).
37. Stevens, K.N. et al. 19p13.1 is a triple-negative-specific breast cancer susceptibility 
locus. Cancer Res. 72, 1795–1803 (2012).
38. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast 
tumours. Nature 490, 61–70 (2012).
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